Understanding Creon 36000-114000 Units
Creon 36000-114000 Units refers to a pancreatic enzyme replacement therapy (PERT) capsule containing 36,000 USP units of lipase, along with corresponding amounts of protease (approximately 114,000 USP units) and amylase, used to treat exocrine pancreatic insufficiency (EPI). 1
What the Numbers Mean
The designation "36000-114000 Unit" describes the enzymatic content per capsule:
- 36,000 USP units of lipase (the primary enzyme for fat digestion) 1
- 114,000 USP units of protease (for protein digestion) 1
- A corresponding amount of amylase (for carbohydrate digestion) 1
The lipase content is the most clinically relevant number, as humans lack alternative mechanisms for fat digestion, making lipase the focus of PERT dosing and meal fat content the primary consideration. 1
Formulation Details
Creon is formulated as enteric-coated microspheres that protect the enzymes from gastric acid inactivation and release them in the duodenum at pH > 5.5. 1, 2 This is one of five FDA-approved PERT formulations, with Creon available in lipase strengths of 3,000/6,000/12,000/24,000/36,000 USP units. 1
Clinical Context and Dosing
Starting Dose Recommendations
The American Gastroenterological Association recommends starting with at least 40,000 USP units of lipase per main meal in adults, meaning the 36,000-unit capsule would typically require supplementation with an additional 6,000-unit capsule (or using a 24,000 + 12,000 combination) to reach the recommended starting dose. 1, 3
For snacks, the dose should be half the meal dose (approximately 20,000 USP units). 1, 3
Timing is Critical
PERT must be taken during the meal, not before or after, as it "treats the meal, not the pancreas" and requires proper mixing with food for optimal enzyme-nutrient interaction. 1, 4, 2 When using multiple capsules, distribute them throughout the meal rather than taking all at once. 4, 2
Dose Adjustment Strategy
Subsequent dosing should be adjusted based on:
- Meal size and fat content 1
- Patient response (reduction in steatorrhea, weight gain, symptom improvement) 1
- Maximum safe dose: 2,500 units/kg/meal or 10,000 units/kg/day 4, 3
For a 70 kg patient, this translates to a maximum of 175,000 units/meal or 700,000 units/day. 4, 3
Common Pitfalls to Avoid
Never use over-the-counter pancreatic enzyme supplements, as they are neither standardized nor regulated, with unknown utility and safety. 1, 4, 2 Only FDA-approved prescription PERT products provide reliable, consistent enzymatic activity. 2
Do not rely on therapeutic trial response for EPI diagnosis, as this is unreliable. 1 Proper diagnosis requires fecal elastase testing (with levels <100 mg/g providing good evidence of EPI). 1
Monitoring Treatment Success
Successful treatment is measured by:
- Reduction in steatorrhea and gastrointestinal symptoms 1
- Weight gain, increased muscle mass and function 1
- Improvement in fat-soluble vitamin levels (A, D, E, K) 1
- Decreased stool frequency and improved consistency 4, 5
Baseline and annual monitoring should include: body mass index, fat-soluble vitamin levels, and DEXA scans every 1-2 years to assess for metabolic bone disease. 1, 3
Additional Therapeutic Considerations
While Creon's enteric coating protects against acid degradation, adding a proton pump inhibitor or H2-receptor antagonist may enhance treatment efficacy if symptoms persist despite adequate dosing. 4, 3 Most patients with EPI are already on acid-reducing agents for this reason. 4, 3
Routine supplementation of fat-soluble vitamins is appropriate, as deficiencies persist even with adequate PERT, and vitamins D and K are specifically associated with osteopathy and fractures in chronic pancreatitis. 1, 3